Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Ki-67 Antigen; a Valuable Prognostic Biomarker for Chronic Lymphocytic Leukemia Publisher



Mehrzad V1 ; Madadi S2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Internal Medicine, School of Medicine AND Cancer Prevention Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Journal of Isfahan Medical School Published:2023


Abstract

Background: Chronic lymphocytic leukemia (CLL) is one of the most common blood malignancies. The chief cells involved in this malignancy are in the G0 phase of cell division and have no proliferative activity; however, what determines the severity and prognosis of this disease is cell proliferation. Ki-67 antigen is a nuclear protein that is present in all cell proliferative phases except G0. The present study was aimed to investigate the prognostic value of Ki-67 antigen expression in patients with CLL and their disease behavior. Methods: The current cross-sectional study has been conducted on 50 CLL patients in 2017. The disease severity based on Rai's staging system, lymphadenopathy, organomegaly, and complete blood count and differentiation (CBC diff) were assessed at study initiation and within six months. Besides, Ki-67 antigen level was assessed via flow-cytometry. Eventually, the prognostic value of Ki-67 antigen to determine CLL prognosis was assessed utilizing Receiver operation curve (ROC) Findings: The study population had the mean age of 64.12 ± 10.42 years old and predominantly consisted of males (68%), and had the mean Ki-67 antigen level of 2.48 ± 1.73 (%). Rai's stage deterioration to 3 or 4, organomegaly, white blood cells (WBC) doubling and concurrent Rai's staging deterioration and WBC doubling (P = 0.002) were directly associated with Ki-67 antigen levels. At the cut-point of 3.44%, Ki-67 antigen had the sensitivity and specificity of 87.5% an 92.9%, with area under the curve (AUC) 0f 0.940 (95%CI: 0.835-0.988; P < 0.001). Conclusion: According to this study, Ki-67 antigen is a valuable prognostic biomarker for CLL progression activity. Besides, at the cut-point of 3.44%, Ki-67 antigen had an acceptable predictive value for the progression manner of CLL disease. © 2023 Isfahan University of Medical Sciences(IUMS). All rights reserved.
Related Docs
1. Association of Killer Cell Immunoglobulin-Like Receptors and Their Cognate Hla Class I Ligands With Susceptibility to Acute Myeloid Leukemia in Iranian Patients, Scientific Reports (2023)
2. Urinary Bk Virus Excretion in Children Newly Diagnosed With Acute Lymphoblastic Leukemia, International Journal of Preventive Medicine (2012)
3. Ki-67 Proliferative Index in Immunoglobulin a Nephropathy; a Pilot Study, Immunopathologia Persa (2022)
4. The Effect of Epstein-Barr Virus Latent Membrane Protein-1 Status on Outcome of Patients With Classic Hodgkin's Lymphoma, Pakistan Journal of Medical Sciences (2008)
5. Circulating Microrna-192 As a Diagnostic Biomarker in Human Chronic Lymphocytic Leukemia, Cancer Gene Therapy (2016)
6. Evaluation of Cd30 Expression in B All and Its Correlation With Mrd(Minimum Residual Disease), Journal of Research in Medical Sciences (2021)
7. Differential Expression Profile of Mir-27B, Mir-29A, and Mir-155 in Chronic Lymphocytic Leukemia and Breast Cancer Patients, Molecular Therapy Oncolytics (2020)
8. Mrna Overexpression of Baalc: A Novel Prognostic Factor for Pediatric Acute Lymphoblastic Leukemia, Biomedical Reports (2015)
Experts (# of related papers)
View all Related Experts
Peyman Bemani (1)
Alaleh Gheissari (1)